Actively Recruiting
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Led by Associazione Angela Serra per la ricerca sul cancro · Updated on 2025-05-06
1000
Participants Needed
6
Research Sites
354 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.
CONDITIONS
Official Title
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Previously untreated patients with a new diagnosis of peripheral T-cell or NK/T-cell lymphoma including various subtypes such as T-cell large granular lymphocytic leukaemia, aggressive NK-cell leukaemia, adult T-cell leukaemia/lymphoma, and others
- Age 18 years or older
- Tissue biopsy sufficient for diagnosis and available for central review
- Clinical data available on disease location, lab tests at staging, treatment details, and follow-up for at least 2 years
- Written informed consent provided
You will not qualify if you...
- Diagnosis of EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood
- Diagnosis of Mycosis fungoides
- Diagnosis of S�e9zary syndrome
- Diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders
- Diagnosis of primary cutaneous peripheral T-cell lymphomas of rare subtypes
- Diagnosis of T-cell lymphoblastic lymphoma/leukemia
- Diagnosis of T-cell prolymphocytic leukemia
- Age under 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Stanford University
Stanford, California, United States, 94305
Not Yet Recruiting
2
IRCCS Istituto Tumori "Giovanni Paolo II"
Bari, Italy, 70124
Actively Recruiting
3
Palermo_La Maddalena
Palermo, Italy, 90146
Not Yet Recruiting
4
Terni-Santa Maria
Terni, Italy, 05100
Not Yet Recruiting
5
Cluj Napoca_Ion Chiricuta Oncology Institute
Cluj-Napoca, Romania, 400015
Actively Recruiting
6
National Cancer Institute
Kiev, Ukraine, 03022
Actively Recruiting
Research Team
M
Martina Manni, MSc, PhD
CONTACT
A
Athina Lymboussakis, MSc, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here